Velcade (Bortezomib) for Lymphoma

Overview
Velcade, also known by its drug name bortezomib, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat mantle cell lymphoma and multiple myeloma. Velcade is often combined with a corticosteroid and other drugs, such as Cytoxan, Revlimid, or Thalomid, in specific chemotherapy regimens.

Velcade is an anticancer drug used in chemotherapy. Velcade is a member of a class of drugs called proteasome inhibitors. Velcade is believed to work by interfering with cell division.

How do I take it?
Velcade is administered as a subcutaneous injection or intravenous infusion.

Side effects
The FDA-approved label for Velcade lists common side effects including nausea, diarrhea, fatigue, nerve pain and tingling, low blood cell counts, constipation, vomiting, rash, fever, and loss of appetite.

Rare but serious side effects listed for Velcade include heart failure, tumor lysis syndrome, fetal harm in pregnant women, low blood pressure that may lead to fainting, and damage to the lungs, liver, or gastrointestinal system.

For more details about this treatment, visit:

Velcade — Takeda
www.velcade.com